ERBB2 and breast cancer: First‐line treatment with the combination of trastuzumab and pertuzumab plus taxane and second‐line treatment with trastuzumab deruxtecan significantly improve the outcome of patients with advanced or metastatic HER2‐positive breast cancer, leading to great enthusiasm to develop novel anti‐HER2 agents.